---
schema_version: "secwatch.filing_event.v1"
accession: "0000785557-22-000013"
form_type: "8-K"
ticker: "DLHC"
cik: "0000785557"
company_name: "DLH Holdings Corp."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:10:07.820954+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DLH Q3 revenue $66.4M (+8% YoY), EPS $0.34, operating margin 10.7%

## Summary
- Revenue $66.4M, up 8% YoY; net income $4.9M vs $2.9M; diluted EPS $0.34 vs $0.21.
- Operating margin improved to 10.7% from 8.0% on higher revenue, better mix, and lower fringe costs.
- Debt reduced to $28.5M from $37.5M at March 31, 2022; total backlog $509.7M.
- Won DoD health R&D IDIQ and NIH National Cancer Institute clinical research contract.
- EBITDA $9.0M (13.5% of revenue) vs $7.0M (11.3%) in prior year.

## SEC filing metadata
- accession: 0000785557-22-000013
- form_type: 8-K
- ticker: DLHC
- cik: 0000785557
- company_name: DLH Holdings Corp.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/0000785557-22-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/dlhc-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000785557-22-000013
- JSON: https://secwatch.observer/filing/0000785557-22-000013.json
- Plain text: https://secwatch.observer/filing/0000785557-22-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.